NCT00581919 · OUTCOME

Overall Survival

Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma · Source last updated 2019-12-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: Full Range
Time frame: From date of randomization until the date of death from any cause, assessed up to 7 years

Groups in this outcome

Bort, Dex, and Dox With ALCAR

Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Bort, Dex, and Dox With ALCAR	32

Reported measurements

Source class 1

Values in months · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Bort, Dex, and Dox With ALCAR	28.3	Not reported	0.2	75.3	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
0.2
upper Limit
75.3
value
28.3

denoms

counts
group Id
OG000
value
32
units
Participants

dispersion Type

Full Range

groups

description
Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long
id
OG000
title
Bort, Dex, and Dox With ALCAR

param Type

MEDIAN

reporting Status

POSTED

time Frame

From date of randomization until the date of death from any cause, assessed up to 7 years

title

Overall Survival

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice